Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started
My Medicine

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Cancer Health Center

Font Size

Celebrex May Slow, Prevent Skin Cancers

Study Shows High-Risk Patients Had Fewer Basal Cell Cancers After Taking Celebrex

Study Ended Early Amid Vioxx Concerns continued...

The study participants were treated with a standard therapeutic dose of Celebrex (200 milligrams, twice a day) or a placebo. Neither the patients nor the investigators knew which treatment was being given.

The treatment arm of the trial was stopped in 2004 in response to concerns raised by the Vioxx studies. Nevertheless, most patients received two years of active treatment and were followed for an additional year.

While both treatment groups continued to develop new cancers during the study, treatment with Celebrex was associated with a 50% decrease in the growth of skin tumors among patients who entered the trial with 15 or fewer skin tumors.

Treatment with the NSAID was also found to reduce the total number of tumors in these patients, but not in patients with more than 15 basal cell carcinoma-related skin lesions at study entry.

The findings appear in the January issue of the journal Cancer Prevention Research.

New Strategy: The Hedgehog Pathway

Tang says it remains to be seen if other oral or even topical NSAIDs can prevent or slow the growth of basal cell carcinomas and other non-melanoma skin cancers.

In an editorial published with the study, Johns Hopkins University oncologist Charles M. Rudin, MD, PhD, writes about another promising skin cancer prevention strategy, which targets something known as the hedgehog pathway.

"The hedgehog pathway is essentially a cell program that is turned on in fetal development but is normally shut off in adult tissue," Rudin tells WebMD. "But in some cancers this pathway is turned on, and basal cell carcinoma is one of those cancers."

In early studies, Rudin and colleagues showed significant reductions in skin lesions when patients with basal cell carcinomas took drugs designed to inhibit, or shut off, the hedgehog pathway.

A trial is now under way in patients with Gorlin syndrome to determine if hedgehog-inhibiting drugs prevent or slow the growth of tumors in this high-risk group.

1 | 2

Today on WebMD

Colorectal cancer cells
New! I AM Not Cancer Facebook Group
Lung cancer xray
See it in pictures, plus read the facts.
sauteed cherry tomatoes
Fight cancer one plate at a time.
Ovarian cancer illustration
Real Cancer Perspectives
Jennifer Goodman Linn self-portrait
what is your cancer risk
colorectal cancer treatment advances
breast cancer overview slideshow
prostate cancer overview
lung cancer overview slideshow
ovarian cancer overview slideshow
Actor Michael Douglas